Supernus Pharmaceuticals, Inc. (SUPN) Financials
SUPN Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 1.3 billion | 374.9 million |
2023-12-31 | 1.4 billion | 487.5 million |
2023-09-30 | 1.3 billion | 373.0 million |
2023-06-30 | 1.3 billion | 373.2 million |
SUPN Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | 38.2 million | 5.9 million |
2023-12-31 | 45.0 million | 6.4 million |
2023-09-30 | 35.7 million | 7.9 million |
2023-06-30 | -19.0 million | 6.1 million |
SUPN Net Income
Graph available only for supporters. Become a supporter to see it.
Date | Net Income |
---|---|
2024-03-31 | 124000 |
2023-12-31 | 1.2 million |
2023-09-30 | -16.0 million |
2023-06-30 | -831000 |
SUPN Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 297.7 million | - | 42.1 million |
2023-12-31 | 254.9 million | - | 41.5 million |
2023-09-30 | 200.2 million | - | 42.3 million |
2023-06-30 | 151.7 million | - | 42.2 million |
SUPN Shares Outstanding
SUPN Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 248000 | 24.3 million | 86.5 million | - |
2023-12-31 | 36000 | 22.7 million | 26.0 million | 55.3 million |
2023-09-30 | 150000 | 22.7 million | 25.9 million | 56.8 million |
2023-06-30 | 159000 | 24.4 million | 26.9 million | 59.9 million |
SUPN Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 143.6 million | 37.1 million |
2023-12-31 | 164.3 million | 41.3 million |
2023-09-30 | 153.9 million | 19.6 million |
2023-06-30 | 135.6 million | 21.1 million |
SUPN
Price: $26.57
52 week price:
Earnings Per Share: 0.02 USD
P/E Ratio: 66.45
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 524852
Ebitda: 27.4 millionMarket Capitalization: 1.6 billion